Table 1 Baseline characteristics of the included studies
Author, Year | Country | Sample size# | Intensive/Standard* (mm Hg) | Achieved SBP target* (mm Hg) | Onset to puncture (minutes)* | stroke severity (NIHSS)* | Primary outcomes | Antihypertensive drugs | Time of duration(h) |
|---|---|---|---|---|---|---|---|---|---|
Mazighi,2021 | France | 318 | 100 ~ 129/130 ~ 180 | 128(11)/ 138(17) | 285 (234,357) /297 (220,353) | 18 (12 ~ 20)/ 17 (13 ~ 20) | abcd | Nicardipine | 24 |
Yang,2022 | China | 816 | < 120/ 140 ~ 180 | NA | NA | 15 (10 ~ 20)/ 15 (10 ~ 20) | abcd | -- | 72 |
Mistry,2023 | USA | 71 | < 140/ < 180 | 122 (15)/ 129 (20) | NA | 16 (11 ~ 23)/ 14 (11 ~ 17) | abc | Nicardipine | 24 |
Nam,2023 | South Korea | 302 | < 140/ 140 ~ 180 | 135(20)/ 141 (20) | 388(224, 693)/ 356(208, 730) | 13(6)/ 12(7) | abc | Nicardipine | 24 |
Ma,2023 | China | 102 | 130 ~ 140/ 160 ~ 180 | 134(8)/ 153(4) | 22/21 | abc | Nitroglycerin | 72 | |
Guan,2024 | China | 80 | 110 ~ 140/<180 | NA | NA | NA | ab | Urapidil | 72 |